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ABSTRACT 
Objective:  Oxidative stress is proposed as an important factor in osteoarthritis (OA).  We 
therefore investigated the expression of the three superoxide dismutase (SOD) antioxidant 
enzymes in OA. 
Methods:  SOD expression was determined by real-time polymerase chain reaction and 
immunohistochemistry using human femoral head cartilage.  SOD2 expression in Dunkin 
Hartley guinea pig knee articular cartilage was determined by immunohistochemistry.  The 
DNA methylation status of the SOD2 promoter was determined using bisulfite sequencing.  
RNA interference was used to determine the consequence of SOD2 depletion on the levels 
of reactive oxygen species (ROS) using MitoSOX
TM
 and collagenases, matrix 
metalloproteinase 1 (MMP-1) and MMP-13, gene expression.   
Results:  All three SOD were abundantly expressed in human cartilage but were markedly 
down-regulated in end-stage OA cartilage, especially SOD2.  In the Dunkin Hartley guinea 
pig spontaneous OA model SOD2 expression was decreased in the medial tibial chondyle 
cartilage prior to, and following, the development of OA-like lesions.  The SOD2 promoter 
had significant DNA methylation alterations in OA cartilage.  Depletion of SOD2 in 
chondrocytes gave an increase in ROS but a decrease in collagenase expression.   
Conclusion:  This is the first comprehensive expression profile of all SOD genes in cartilage 
and importantly, using an animal model, we show that a reduction in SOD2 is associated 
with the earliest stages of OA.  We found that a decrease in SOD2 associates with an 
increase in ROS and but a reduction of collagenase gene expression, demonstrating the 
complexities of ROS function.  
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INTRODUCTION 
Osteoarthritis (OA) is a common degenerative joint disease characterised by focal 
degradation of articular cartilage, centred on load-bearing areas.  The primary risk factor for 
OA development is age, but the mechanisms by which ageing contributes to OA 
susceptibility and progression remain poorly understood.  Articular cartilage extracellular 
matrix (ECM), which is maintained by chondrocytes, undergoes significant changes in 
structure and composition with age, closely linked to a decline in chondrocyte function.[1, 2]  
Many studies have identified molecular characteristics of ageing in OA cartilage or 
chondrocytes which may contribute to the onset of OA including telomere genomic 
instability, formation of advanced glycation end-products, increased apoptosis and 
senescence.[3]  Many such changes could be associated with the elevated levels of 
oxidative stress that occur in OA and aged cartilage [4], leading to an altered chondrocyte 
phenotype that renders cells unable to respond effectively to normal loading regimes [5] and 
potentially contributes to disease onset. 
Although generally considered a hypoxic environment, oxygen diffuses through articular 
cartilage and is utilised by chondrocytes to derive approximately 25% of their ATP.  
Oxidative phosphorylation is a major source of reactive oxygen species (ROS) however, 
chondrocytes also express NADPH oxidase (NOX) and nitric oxide synthase (NOS) family 
members along with various oxygenases which principally generate the ROS nitric oxide 
(NO) and the superoxide anion (O2
•).[4]  These ROS generate derivatives including 
hydrogen peroxide (H2O2), peroxynitrite (ONOO
-
) and hydroxyl radicals (OH
•
).  ROS are 
highly reactive and therefore transient so their production in cartilage has been determined 
indirectly; an accumulation of lipid peroxidation products [6] and nitrotyrosine residues [7] 
have been observed in aged and OA cartilage.  ROS are able to cause cartilage degradation 
directly by cleaving collagen, aggrecan and activating matrix metalloproteinases (MMP) [8-
10], a family of enzymes that play a key role in cartilage destruction in OA.[11]  ROS also act 
indirectly by modulating redox-sensitive signalling pathways that control MMP expression  
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and in cultured chondrocytes may lead to decreased collagen and aggrecan synthesis.[12, 
13]
To prevent an accumulation of ROS-mediated damage chondrocytes produce a number of 
antioxidant enzymes including the superoxide dismutases (SOD), catalase and glutathione 
peroxidase.[4]  There are three SOD family members; SOD1 (Cu/Zn-SOD) found principally 
in the cytosol, SOD2 (Mn-SOD) found in the mitochondrial matrix and SOD3 (EC-SOD) 
found in the ECM.  The SOD family catalyse the dismutation of O2
•
 to O2 and H2O2, thereby 
limiting the formation of highly aggressive compounds such as ONOO- and OH•.
SOD2 has been shown to be down regulated in OA cartilage.[14, 15]  SOD3 is also 
decreased in human OA cartilage and in a mouse model of OA.[16]  SOD3 deficient mice 
show an increased severity of collagen-induced arthritis (CIA).[17]  Together, these and 
other data have led to the proposal that supplementary antioxidants may represent a 
potential therapy for OA.[18] 
We considered that the SOD family may play a key role in controlling ROS levels in cartilage 
and that any deficiency may account for the elevated oxidative stress observed.  Here we 
report a significant decrease in the expression of all SOD family members in OA cartilage 
compared to macroscopically normal cartilage (from neck of femur (NOF) fracture patients) 
at both the RNA and protein levels.  We also show a decline in SOD2 expression correlates 
with the onset of, and importantly precedes, OA-like lesions in an animal model.  We also 
demonstrate that the SOD2 promoter is significantly differentially methylated in OA 
compared to NOF cartilage, representing a potential mechanism for the reduction in 
expression observed in OA.  Functionally, SOD2 depletion in chondrocytes resulted in a 
significant increase in ROS but a decrease in the interleukin (IL)-1-induced levels of MMP-1 
and MMP-13.  Together our data suggest a decrease in SOD2 expression may be pre-
symptomatic of disease and potentially an attempt to reduce the expression of collagenases, 
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enzymes which contribute to cartilage degradation, but concomitantly also contributes to 
increased oxidative stress. 
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MATERIALS AND METHODS
Materials 
Antibodies against SOD1 and SOD2 were from Stressgen Bioscience (Cambridge, UK) and 
SOD3 from Abcam (Cambridge, UK).  Rabbit IgG isotype control antibody, oligonucleotides 
(Table 1), PCR Mastermix and 5-aza-2’-deoxycytidine (AZA) were from Sigma-Aldrich 
(Poole, UK).  Anti-rabbit Vectastain ABC Elite kit and Vectashield were from Vector 
Laboratories Ltd. (Peterborough, UK).  Recombinant human IL-1α was a gift from 
GlaxoSmithKline (Stevenage, UK).  Taqman Low Density Arrays (TLDA) were from Applied 
Biosystems (ABI, Foster City, CA, USA).  Sybr-Green Mastermix was from Invitrogen 
(Paisley, UK).  SmartPoolTM small interfering RNA (siRNA) against SOD2 (Table 1) and 
siControl2 were from Dharmacon (Cramlington, UK). 
RNA Extraction from Cartilage Samples, Chondrocyte Isolation and Cell Culture 
Articular cartilage was obtained from patients undergoing joint replacement surgery.  Hip 
cartilage samples from OA patients were compared to lesion-free cartilage from fracture to 
the neck of femur (NOF) patients with no known history of joint disease.  Femoral heads 
were processed and RNA extracted using established methodology.[19]  Human articular 
chondrocytes (HAC) were isolated from OA cartilage and cultured as previously 
described.[20]  This study was performed with Ethical Committee approval from Norfolk and 
Norwich University Hospital Trust, Oxford Radcliffe Hospitals NHS Trust and Newcastle and 
North Tyneside Health Authority and all patients provided informed consent. 
Real-Time RT-PCR and siRNA-Mediated Gene Silencing 
RNA interference (RNAi) in HAC was as previously described [19] with the siRNA used at 
100 nM.  Briefly, 2.5 x 104/cm2 (HAC) cells were seeded overnight and the following day 
transfected with Dharmafect 1 (Dharmacon) and siRNA (SOD2 (Table 1) or non-targeting 
control, siControl2).  Cells were washed 24 hours post-transfection with phosphate buffered 
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saline (PBS) and cultured in serum-free medium for a further 24 hours prior to 24 hour 
stimulation ± 0.05ng/mL IL-1, or as described.  Total RNA was isolated using the Cells-to-
cDNA II Kit (ABI) and MMP-1 and MMP-13 expression determined by real-time RT-PCR as 
previously described.[19]  Gene depletion was confirmed by real-time RT-PCR and 
immunoblotting of total cell lysates prepared as described.[19]  SOD family gene expression 
in cartilage cDNA was assessed using a TLDA according to manufacturer’s (ABI) 
instructions and as previously described.[19]  Throughout, mRNA levels were normalised to 
a housekeeping gene (ABI) using the calculation 2
-∆Ct
.
Immunohistochemistry 
Human Patient Samples: Serial sections (12µm) were prepared and processed from full-
depth cartilage taken from intact cartilage of OA and NOF femoral heads as previously 
described.[21]  Serial sections were incubated for 60 minutes at room temperature (RT) with 
either a polyclonal primary (rabbit) antibody to a SOD or a normal rabbit IgG isotype-
matched control.  All antibodies were used at a concentration of 1 µg/mL except for SOD3 
which was used at a 1:2000 dilution.  All antibodies were prepared in PBS containing 1.5% 
(v/v) normal goat serum.  
Dunkin Hartley Guinea Pig Knee Samples:  Male Dunkin Hartley guinea pigs (Harlan Olac, 
UK) aged from 1 to 8 months (five per group) were used for histology. Animals were 
humanely sacrificed according to UK Home Office regulations.  Tibial heads were fixed in 
4% (v/v) formaldehyde for 2 days and decalcified in 0.1 M EDTA (pH 7.0) in PBS for 3 
weeks. Blocks that included articular cartilage and bone (lateral and medial tibial plateaus) 
were dehydrated and embedded in paraffin.  Five µm-serial, coronal sections were 
deparaffinised with xylene and rehydrated through a graded ethanol series and finally 
incubated in 10 mM sodium citrate buffer, pH 6.0, for 2 hours at RT, followed by 3% (v/v) 
H2O2 in tris-buffered saline (TBS) for 15 minutes.  Serial sections were blocked with 1.5% 
(v/v) normal goat serum in TBS for 30 minutes and then incubated for 90 minutes at RT with 
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an antibody to SOD2 or normal rabbit IgG (1 µg/mL in TBS/1.5% (v/v) normal goat serum).  
The remainder of the staining procedure and mounting was performed as previously 
described.[21]  Representative sections from each animal were stained with safranin ‘O’/fast 
green (0.02% (w/v) fast green for 3 minutes, 1% (v/v) acetic acid for 30 seconds, 0.1% (w/v) 
safranin ‘O’ for 5 minutes).   
MitoSOXTM Red staining 
HAC were transfected with siRNA against SOD2 or a control (see above) and 24 hr later 
serum starved overnight. Cells were then stained with 2 µM MitoSOXTM Red (Invitrogen) in 
serum-free media for 15 min at 37°C, washed twice in PBS for 5 min and fixed in 4% (w/v) 
cold paraformaldehyde in PBS for 10 min at RT or for SOD2 staining, permeabilised and 
blocked with 0.5% (v/v) Saponin/PBG (0.5% (w/v) BSA solution/0.2% (v/v) fish skin gelatin) 
in PBS for 10mins at RT, incubated with 1µg/ml rabbit anti-human SOD2 antibody in 0.5% 
Saponin/PBG for 45mins at RT, washed twice with 0.5% Saponin/PBG and then incubated 
with secondary antibody (goat anti-rabbit Alexa 488) (1:750 in 0.5% Saponin/PBG) for 
45mins at RT, before fixing as above. All slides were washed twice with PBS and mounted in 
Vectashield and visualised using confocal microscopy.  
Image analysis 
Fluorescent and immunohistochemical images were analysed using ImageJ analysis 
software (Wayne Rasband, NIH, USA). For fluorescent images, individual cells from random 
fields were selected and the average red (MitoSOXTM Red) and/or green (SOD2) pixels 
present in the cell (per area) calculated after average background subtraction. 
Immunological staining from cartilage sections was quantified per section area for SOD3 or 
on a per cell basis for SOD1 and SOD2. 
DNA Methylation Analysis 
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HAC were cultured ± 10 µM AZA for 35 days prior to RNA isolation with fresh AZA added 
daily.  SOD2 expression was determined by real-time RT-PCR.  Genomic DNA (gDNA) was 
purified from cartilage samples during RNA extraction [22] by ethanol precipitation of the first 
wash of Qiagen RNeasy columns (Qiagen, Crawley, UK).  200-300ng gDNA was bisulfite-
treated using the Epitect Bisulfite kit (Qiagen).  PCR was performed to amplify a SOD2 
promoter region from 10-15 ng bisulfite-treated gDNA using Titanium Taq (TaKaRa 
Biomedicals, Wokingham, UK).  PCR conditions were: 95°C 1 min, (95°C 15 sec, 64.2°C 30 
sec, 68°C 1 min) x 40 cycles, 68°C for 7 min.  PCR products were cloned and DNA 
sequenced until ten unique clones from each patient sample were obtained.  DNA 
methylation analysis was performed using the BiQ analyzer software.[23]  
Statistical Analysis 
Differences between NOF and OA groups and cultured cell treatments were defined using a 
two-tailed Mann-Whitney U test.  Fisher's exact test was used for statistical analysis of DNA 
methylation.  Student’s t-tests were performed when quantifying the level of immunological 
or MitoSOX
TM
 staining. 
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RESULTS 
 
The SOD gene family are highly but differentially expressed between NOF and OA 
human cartilage 
A screen for SOD expression found all three genes to have significantly reduced expression 
in OA compared to NOF cartilage.  The median expression levels of SOD1, SOD2 and 
SOD3 were reduced 3.4 (P=0.0014), 41.5 (P≤0.0001) and 3.9 (P=0.0009) fold respectively 
in OA cartilage.  This reduction in SOD2 and SOD3 expression compares with previous 
reports.[14, 16]  The quantitative nature of this screen revealed the very high abundance of 
all the SOD family, particularly SOD2, with the relative abundance of each in NOF samples 
being: SOD2>>SOD3>ACTB>SOD1 (Fig. 1). 
To validate our RNA expression data we performed immunohistochemistry using OA and 
NOF cartilage (Fig. 2A).  As expected SOD1 expression was cellular with staining obvious 
throughout the sections (i.e. from articular surface to subchondral bone), though staining 
was more intense at the articular surface.  Staining within the full-depth cartilage was 
significantly reduced in OA sections (Fig. 2B).  SOD2 staining was cellular and strongest 
near the articular surface.  There was a clear, significant, decrease in the expression of 
SOD2 in the surface zones of the diseased tissue though the protein was still detected.  A 
SOD3 antibody gave the expected diffuse staining pattern representative of ECM staining.  
This was visible throughout the tissue though staining was more intense at the articular 
surface and again significantly reduced in OA compared to NOF cartilage.  
SOD2 expression declines prior to the appearance of OA erosions 
Since the changes in SOD2 expression were most significant we next ascertained its 
expression during the onset of OA using joint sections from an age-range of Dunkin Hartley 
guinea pigs; an established model of spontaneous OA [24].  In this model the medial tibial 
plateau develops OA-like lesions as the animal ages, whilst the lateral tibial plateau 
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develops significantly fewer lesions as highlighted by cellular and surface changes together 
with a decrease in safranin ‘O’ staining, representative of  proteoglycan loss (Fig. 3).  In 
young animals (1 month) SOD2 staining was strongest near the articular surface of both 
medial and lateral plateaus (Fig. 3A), as observed in human NOF cartilage (Fig. 2).  At 4 
months of age OA-like lesions could be observed on the medial but not lateral plateau.  
Concomitantly SOD2 expression was significantly reduced in the diseased medial, but not 
the normal lateral plateau (Fig. 3A & B).  Interestingly, SOD2 expression within the medial 
plateau significantly declined prior to observation of lesions (i.e. in 2 month old animals) 
suggesting that this change in expression may be symptomatic of early changes in OA (Fig. 
3A & B). 
The SOD2 promoter is differentially methylated between NOF and OA cartilage 
As SOD2 promoter hypermethylation correlates with decreased gene expression (e.g. [25]), 
we investigated the role that DNA promoter methylation may play in the SOD2 down-
regulation observed in OA chondrocytes.  Firstly we found that SOD2 expression increased 
2-fold (P≤0.001) in OA HAC treated with the DNA demethylating agent AZA (Fig. 4A), 
indicating a role for DNA methylation in SOD2 regulation.  Next, we analysed a region of the 
SOD2 promoter upstream of the transcription start site at -297 to -87 (Supp. Fig. 1) known to 
be subject to differential methylation.[25]  Bisulfite sequencing of on average 9.6 clones from 
each of 12 OA and NOF patient cartilage samples identified three CpG sites, CpG6, 10 and 
14, corresponding to nucleotides -222, -183 and -154 respectively, with significant 
differences in methylation status between NOF and OA cartilage (Fig. 4B).  CpG14 and 
CpG10 showed significantly (P≤0.001 and P≤0.05 respectively) lower methylation in OA 
cartilage whereas CpG6 was more methylated (P≤0.001).  CpG14 is encompassed within a 
putative AP-2 binding site while CpG10 is located at a single nucleotide polymorphism (SNP) 
(NCBI reference rs2758343).  Overall OA cartilage had, as hypothesised, a significant 
increase (P≤0.05) in methylated CpG.  
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SOD2 depletion modulates MMP-1 and MMP-13 expression in HAC 
A reduction in SOD levels are likely to lead to an increase in ROS. Since SOD2 is localised 
to the mitochondria, the major source of ROS, we used the mitochondria-targeting 
MitoSOXTM Red, which is oxidized by O2•, but not other ROS or reactive nitrogen species, to 
confirm that SOD2 depletion increased O2• levels in chondrocytes (Fig 5A & B).   A further 
consequence of a reduction in SOD2 is a decrease in H2O2 which acts as an intracellular 
signalling moiety.[26]  Hence, we tested whether a reduction in SOD2 in chondrocytes would 
effect basal and pro-inflammatory cytokine (IL-1) induced collagenase (MMP-1 and MMP-13) 
expression.  RNAi depletion of SOD2 in chondrocytes (Fig. 5C) resulted in a significant 
reduction of basal MMP-1 but not MMP-13 expression (Fig. 5D).  OA has an inflammatory 
component [27] and IL-1, a potent inducer of SOD2 and the collagenases, can be detected 
within the OA joint.  In line with this, IL-1 stimulation led to a robust increase in SOD2 and 
collagenase expression.  However, depletion of SOD2 significantly decreased the IL-1-
induced expression of both collagenases (Fig. 5E). 
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DISCUSSION 
Here we found that all of the SOD family of antioxidant enzymes are highly expressed in 
NOF human cartilage in relation to an established housekeeping gene, which suggests that 
cartilage must generate significant levels of ROS and that ROS scavenging is necessary for 
tissue maintenance and homeostasis.[28]  Our findings show that the expression of all SOD 
enzymes is significantly reduced in diseased cartilage, confirming and expanding on 
previous data for SOD2 and SOD3.[14-16]  Regan et al., found that SOD3 was reduced in 
OA compared to normal (again, hip fracture) human tissue and in the cartilage of the STR/ort 
mouse spontaneous OA model, interestingly also before histological evidence of 
disease.[16]  SOD3 levels in synovial fluid are also reduced in OA patients compared to 
patients with injured/painful joints but no cartilage damage.[29]  We have now shown not 
only that SOD2 expression is significantly down regulated in OA chondrocytes in vivo, but 
that this precedes the development of OA lesions in the Hartley guinea pig, raising the 
possibility that alterations in SOD2 expression are associated with the earliest stages of OA 
pathogenesis. 
SOD2 expression is subject to epigenetic control via promoter DNA methylation in a number 
of carcinoma cell-lines.[25]  Furthermore, aberrant DNA methylation occurs with disease and 
ageing.[30]  In chondrocytes, SOD2 expression increased following inhibition of DNA 
methylation (Fig 4A) and analysis of the SOD2 promoter identified a significant overall 
increase in the number of CpG sites partially methylated in OA compared to NOF cartilage 
(Fig 4B).  Promoter DNA methylation is generally repressive to transcription, thus even the 
modest increase in CpG methylation observed here may significantly impact on the SOD2 
expression level.  Re-instigation of SOD2 expression using DNA methyltransferase inhibitors 
is one way in which they may benefit OA patients, as proposed.[31]  
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SOD are required for the conversion of reactive O2
•
 to O2 and H2O2 thus a down-regulation 
of SOD would increase oxidative stress, which is implicated in a number of pathologies 
including arthritis.[32]  As such, research has investigated the consequences of modulating 
SOD levels in both cells and animal models.  SOD1 and SOD3 knockout mice display 
relatively mild phenotypes [33] but exhibit an increase in oxidative stress markers.[34]  
SOD2 deletion in mice results in lethality by neonatal day 10.[35] SOD2 is localised to the 
mitochondria and dismutates O2
• produced as a by-product of oxidative phosphorylation.  
The depletion of SOD2 is proposed to lead to increased mitochondrial DNA mutation and 
subsequent dysfunction.  Interestingly, mitochondrial DNA mutations increase in OA [36], 
and mitochondrial DNA haplogroups themselves contribute to the pathogenesis of OA.[37] 
The combined effect of a decrease in all three SOD enzymes could significantly contribute to 
the increased oxidative stress observed in OA cartilage.[38]  Using RNAi we confirmed that 
depletion of SOD2 from chondrocytes leads to an increase in O2•, which can result in 
telomere instability and a down regulation of chondrocyte function [38] as well as damage to 
cartilage macromolecules such as hyaluronan and collagen [9, 39].  A ROS increase could 
also potentially contribute to the onset of senescence, which may play a role in OA.[1]  
Together these and other data would suggest that SOD have a protective role in the joint 
and cartilage.  However, the results here demonstrate that down-regulation of SOD2 is in 
part chondroprotective, reducing the activation of redox-sensitive signalling pathways and 
thus collagenase expression.  Similarly in fibroblasts, SOD2 over-expression increases 
MMP-1 expression via increased H2O2-dependent activation of ERK1/2 [40] and AP-1 [41], 
while SOD2-deficient fibroblasts cannot induce MMP-1 and MMP-13 following cytokine 
stimulation.[40]  It is therefore perhaps unsurprising that the depletion of SOD2 in HAC 
resulted in the decreased basal MMP-1, an observation seen in end-stage OA [22], as well 
as decreased production of both collagenases following IL-1 stimulation (Fig. 5),  
presumably by reduced H2O2 levels.  H2O2 levels are also controlled by catalase whose 
expression we found to be significantly increased in OA cartilage (not shown); indeed, 
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increased catalase expression can reverse the H2O2-mediated induction of MMP-1 in 
fibroblasts.[40]  Therefore one potential benefit of a down-regulation in SOD2 would be to 
reduce the expression of matrix-degrading enzymes by modulation of redox-controlled 
signalling pathways.  However, the role of ROS is complex and increased levels can actually 
activate latent MMP [8] while more aggressive ROS such as ONOO-, generated from O2
•
and NO, can also modulate redox-sensitive signalling pathways.[42]  As a result, the 
elucidation of the overall consequences of SOD2 down regulation requires more detailed 
analysis of both the levels of O2
•
 present in NOF and OA chondrocytes as well as activity of 
the associated redox-sensitive signalling pathways. 
Several studies have used antioxidants as treatments for arthritis (reviewed in [18]).  Ex vivo
SOD3 gene transfer or SOD mimetics (e.g. M40403) can reduce the severity of CIA in 
models [43, 44] and recombinant SOD1 can inhibit cartilage damage in hens.  Intra-articular 
injections of bovine SOD1 (Orgotein) have also been trialled in OA patients with some 
success, however the drug was withdrawn due to adverse side effects (reviewed in [18]).  In 
terms of dietary supplements, vitamins have been shown to decrease OA development and 
increase the expression of antioxidant enzymes in an OA model.[18]  However, 
epidemiological studies examining the benefits of antioxidants in human OA, especially 
vitamin E (α-tocopherol), are contradictory (reviewed in [4]).  
In conclusion, this is the first detailed study to examine the expression of all three SOD 
antioxidant enzymes in cartilage and OA.  Our data clearly shows a decrease in the 
expression of all three enzymes in OA cartilage, with SOD2 and SOD3 expression 
decreasing before the appearance of histologically detectable lesions.  ROS are normal and 
useful metabolites, serving important roles in a number of processes, including as a 
signalling molecule.  Depletion of SOD2 reduced the IL-1-induced expression of MMP-1 and 
MMP-13, indicating that the decrease of SOD2 expression in OA cartilage may represent a 
chondroprotective mechanism.  However, SOD2 depletion also lead to an increase in ROS 
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and such an overproduction, as occurs in injury, disease, or ageing, can lead to cell 
dysfunction and death.[32] Clearly the balance of ROS levels and the consequences of 
altered levels on cartilage are complex.  Further work is required to determine whether the 
decrease in antioxidant enzymes reported here are an attempt by the joint to reduce 
cartilage destruction mediated by modulating the levels of the collagenases but which 
ultimately leads to an increase in ROS and loss of cartilage homeostasis.  Such information 
is pertinent if antioxidant treatments hold the key to potential OA therapies. 
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Table 1. Oligonucleotides: real-time RT-PCR, bisulfite PCR primers and SOD2 
siGENOME SMART pool siRNA sequences. 
Gene Method Primer Sequence 
SOD2 Sybr Green RT-PCR Forward 
Reverse
5’-CTGGACAAACCTCAGCCCTA 
5’-TGATGGCTTCCAGCAACTC 
SOD2 DNA Methylation Analysis Forward 
Reverse
5’-GTAATTAAAATTTAGGGGTAGG 
5’-AAAAAAAACTACAAACTAACCTC 
SMARTpool
Duplex 
Target Strand  Sequence 
1 Sense 
Antisense 
5’-GGACAAACCUCAGCCCUAAUU 
5’-PUUAGGGCUGAGGUUUGUCCUU 
2 Sense 
Antisense 
5’-GGAGCACGCUUACUACCUUUU 
5’-PAAGGUAGUAAGCGUGCUCCUU 
3 Sense 
Antisense 
5’-AAAGAUACAUGGCUUGCAAUU 
5’-PUUGCAAGCCAUGUAUCUUUUU 
4 Sense 
Antisense 
5’-GUAAUCAACUGGGAGAAUGUU 
5’-PCAUUCUCCCAGUUGAUUACUU 
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Figure Legends 
Figure 1. Comparison of superoxide dismutase (SOD) gene expression between cartilage 
from neck of femur (NOF) and osteoarthritis (OA) patients. SOD family gene expression was 
determined by real-time reverse transcriptase polymerase chain reaction (RT-PCR) from 
cartilage RNA isolated from 12 NOF (open) and 12 OA patients (shaded). Gene expression 
data are presented as a ratio of SOD gene levels to that of the housekeeping gene Actin B 
(ACTB) using the calculation 2-∆CT. Lines within the boxes represent the median, the boxes 
represent the 25th and 75th percentiles, and the lines outside the boxes correspond to the 
minimum and maximum values. Presented P values were calculated using the Mann-
Whitney U-test, where * represents P<0.05, ** P<0.01 and *** P<0.001. 
Figure 2.  Immunohistochemical analysis of SOD expression in representative specimens of 
human articular cartilage from NOF and OA patients. A, Sections were subjected to 
immunohistochemistry using the labelled anti-SOD or normal rabbit IgG (negative control) 
and counterstained with haematoxylin.  Full-depth sections are shown at x 5 magnification 
and for clarity the articular surface is shown at x 20. Images are representative of sections 
from 5 NOF and 5 OA patients. B, immunohistochemical images, of fixed exposure, from 5 
NOF and 5 OA patients were quantified using the ImageJ software. For each image the 
percentage staining in each field of view (FOV) was calculated and the mean with standard 
error of the mean (SEM) NOF and OA FOV presented. Percentage FOV was calculated for 
full depth sections or dividing the section into two quadrants ‘deep’ and ‘surface’. P values 
were calculated using Student’s t-test, where * represents P<0.05 and ** P<0.01. 
Figure 3. Immunohistochemical analysis of SOD2 expression in representative specimens 
of Dunkin-Hartley guinea pig articular cartilage. A, Cartilage sections are representative of 5 
animals at each time point (1 to 12 months of age). Sections were either stained with 
safranin ‘O’ as a marker of proteoglycan or subjected to immunohistochemistry using the 
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labelled anti-SOD2 or normal rabbit IgG (negative control – data not shown). Lateral and 
medial tibial plateaus are as indicated. Images shown are at x 10 magnification, unless 
indicated otherwise.  B, Immunohistochemical images of lateral and medial tibial plateaus, of 
fixed exposure, from 5 animals were quantified using the ImageJ software. For each image 
the percentage staining in each field of view (FOV) was calculated. For each age group the 
staining in the lateral plateau is arbitrarily 100% + SEM. P values were calculated using 
Student’s t-test, where * represents P<0.05 and ** P<0.01. 
Figure 4. Analysis of the regulation of SOD2 in human articular chondrocytes (HAC) by DNA 
methylation. A, Primary HAC were treated with the DNA demethylating agent 5-aza-
2'deoxycytidine (AZA) for 35 days (2 passages) as described and SOD2 expression 
measured by real-time RT-PCR and normalised to GAPDH expression levels. Data is 
presented fold over control and error bars represent SEM.  Data is combined from four HAC 
populations treated in duplicate. Statistical significance was calculated using the Mann-
Whitney U-test, where *** represents P<0.001. B, DNA methylation analysis of the SOD2 
promoter in cartilage genomic DNA from neck of femur (NOF) and osteoarthritis (OA) 
patients.  Genomic DNA from cartilage of 12 NOF and 12 OA patients was analysed to 
determine the methylation status of the SOD2 promoter region spanning 19 potential CpG 
dinucleotides. An average of 9.6 non-clonal DNA sequences per patient sample were 
analysed and the methylation percentage for each is plotted. Methylation CpG sequences 
are represented by black bars, open are non-methylated and the bar is grey when the CpG 
sequence was not detected, generally due to a SNP at that locus (e.g. CpG10).  Fisher's 
exact test was used for statistical analysis, where * represents P<0.05 and ** P<0.01. 
Figure 5. Functional consequences of SOD2 depletion. A and B, SOD2 depletion (green) by 
RNAi led to a significant increase in MitoSOXTM Red mitochondrial staining as determined by 
confocal microscropy. Data are taken from four patient chondrocyte preparations. Images 
were quantified using ImageJ software on a per cell basis from random field images. P 
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values were calculated using a Student’s t-test, where ** represents P<0.01 and *** P<0.001 
C-E, Depletion of SOD2 leads to reduction in collagenase gene expression. C, transfection 
of primary human articular chondrocytes (HAC) from OA patients with siRNA to SOD2 
(siSOD2) for 48 hours under basal conditions (24 hour serum free) compared to transfection 
with an equivalent amount (100nM) of a non-targeting control siRNA (siCon) resulted in a 
highly significant approximately 80% reduction in SOD2 RNA level as determined by real-
time RT-PCR. Concomitantly a substantial reduction in SOD2 protein expression was 
measured by immunoblotting (an anti-GAPDH antibody was used as a protein loading 
control). D, MMP-1 and MMP-13 basal expression levels were measured as described 
above. SOD2 RNAi resulted in a significant reduction in MMP-1 but no change in the levels 
of MMP-13. E, interleukin-1 (IL-1, 0.05 ng/ml) stimulation for 24 hours induced the 
expression of SOD2, MMP-1 and MMP-13, however the induced-expression of all three 
genes was significantly reduced when SOD2 was depleted by RNAi (siSOD2). Throughout 
RNA expression levels were normalised to the 18S gene and data plotted as fold over 
control levels. Data presented are from a single experiment (n=8) using cells from one 
donor. The experiment was performed three times using different patient cell populations. P 
values were calculated using the Mann-Whitney U-test, where * represents P<0.05, ** 
P<0.01 and *** P<0.001. Error bars shown are SEM. 
Supplementary Figure 1. The SOD2 promoter. Bioinformatic analysis of the SOD2 
promoter was performed using genomatix software.  The DNA sequence is numbered with 
respect to the published transcription start site (+1) of RNA transcript NM_000636 (Genbank 
ID).  Exonic sequence is shown in bold typeface and intronic in lower case.  Intron 1 splice 
site acceptor and donor sequences are underlined.  CpG sequences analysed by bisulfite 
sequencing are shown in bold typeface and numbered consecutively. Dotted arrowed lines 
indicate the locations of bisulfite primers (Table 1) used to PCR amplify the bisulfite 
converted SOD2 promoter. Putative binding sites for the factors are shown above (+ 
orientation) or below (- orientation) the appropriate DNA sequences. SNP (rs2758343) at 
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CpG10 is depicted. This is predicted to cause the loss of a putative HIF-1 binding site to 
become a FTF site (dashed line). HIF-1, hypoxia inducible factor-1; FTF, alpha fetoprotein 
transcription factor.
Supplementary Figure 2. DNA methylation analysis of the SOD2 promoter of neck of femur 
(NOF) and osteoarthritis (OA) patient cartilage genomic DNA. Figure is essentially as 
described for Figure 4 but data from all clones sequenced for each patient is presented in 
the form of a lollipop plot [23]. Open circles show non-methylated CpG dinucleotides, filled 
represented a non-converted, therefore methylated CpG. A vertical line indicated the lack of 
a CpG sequence at that locus for the individual clone. A, NOF patient samples. B, OA 
patient samples. 





